Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva Foresees Sustained Growth Despite Slow Start To Fiscal 2006

This article was originally published in The Pink Sheet Daily

Executive Summary

Generics firm expects growth from generic Pravachol and generic Zocor exclusivity periods.

You may also be interested in...

Copaxone Sales Will Continue Growth Regardless Of Tysabri Re-Launch, Teva Says

Teva expects sales of its multiple sclerosis therapy Copaxone (glatiramer)to continue to grow in 2006 regardless of whether FDA allows the re-launch of competitor Tysabri (natalizumab)

Statin Prices Likely To Remain High After Zocor Exclusivity Win

Teva and Ranbaxy appear slated for 180 days of simvastatin exclusivity after federal court ruling postponing mass generic entry into the sector until 2007.

Teva Launches Pravachol Generic; Ranbaxy Stuck At FDA

Watson also enters into the pravastatin market with an authorized generic.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts